Stockscreener 앱 받기
240.57
0.37%
-0.89
시간 외 거래:
240.57
전일 마감가:
$241.46
열려 있는:
$242.01
하루 거래량:
481.99K
Relative Volume:
0.55
시가총액:
$15.62B
수익:
$4.44B
순이익/손실:
$29.49M
주가수익비율:
-13,074.46
EPS:
-0.0184
순현금흐름:
$1.19B
1주 성능:
-0.11%
1개월 성능:
-5.39%
6개월 성능:
+33.19%
1년 성능:
+84.79%
1일 변동 폭
$239.78
$243.21
1주일 범위
$238.53
$247.31
52주 변동 폭
$125.78
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
240.57 | 15.96B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 재개 | Raymond James | Outperform |
| 2026-02-27 | 개시 | Barclays | Overweight |
| 2025-11-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-15 | 개시 | Deutsche Bank | Buy |
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Learn Why The Bull Case For Jazz Pharmaceuticals Stock Could Change Following FDA Drug Approval - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and a 17.28% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Stock Price Forecast. Should You Buy JAZZ? - StockInvest.us
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone? - Yahoo Finance
Four September conference talks will include Jazz Pharmaceuticals - Stock Titan
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? - Yahoo Finance
Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth - insights.citeline.com
Jazz Pharmaceuticals PLC (JAZZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Stock Trading Below Its Worth - ChartMill
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences - PR Newswire
Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next - simplywall.st
Insider plans more Jazz (NASDAQ: JAZZ) share sales—but how big is this next trade? - Stock Titan
JAZZ Rises on Updated OS Results From Gastric Cancer Study - Yahoo Finance
Canaccord reiterates Jazz Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Nigeria
Jazz reports Phase III trial interim results for Ziihera combination - clinicaltrialsarena.com
Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032 - TradingView
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 1,527 shares in 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
No-Moat Jazz's Growth Supported by Strong Clinical Data for Ziihera and Expanding Opportunity - Morningstar
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares in 2026 - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans $858K stock sale - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director may sell 3,507 shares - stocktitan.net
Jazz Pharmaceuticals (NASDAQ: JAZZ) director lines up 3,852-share sale for 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director may sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans sale after 18,000 shares sold - Stock Titan
Positive Phase 3 Survival Results in HER2+ Advanced GEA – Jazz Pharmaceuticals - Oncodaily
Cancer drug decision could swing Jazz Pharmaceuticals' beatBizwomen - The Business Journals
JAZZ Looks 61.2% Overvalued on GF Value™ as Positive Trial Data Boosts Sentiment - GuruFocus
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA - PR Newswire
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Jazz Pharmaceuticals Plc 주식 (JAZZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GALA RENEE D | President & CEO |
Sep 08 '26 |
Sale |
243.03 |
2,000 |
486,060 |
143,394 |
0.14%
0.15%
자본화:
|
볼륨(24시간):